^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    FMS kinase inhibitor

    Related drugs:
    8d
    Microglial Inflammatory Response in the Glioblastoma Microenvironment in Preclinical Models. (PubMed, Mol Neurobiol)
    Microglia inhibition or depletion by treating organotypic cultures with minocycline or PLX3397 resulted in reduced levels of all the evaluated cytokines in the medium, confirming the role of microglia in the inflammatory microenvironment of glioblastoma. These findings provide valuable insights into how microglia interact with tumors and healthy cells in the tumor microenvironment, driving neuroinflammation and tumor cell dedifferentiation. This understanding could pave the way for the development of innovative therapies for glioblastoma.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • NES (Nestin)
    |
    Turalio (pexidartinib) • minocycline
    29d
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin • Romvimza (vimseltinib)
    1m
    A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=48, Recruiting, Deciphera Pharmaceuticals, LLC | N=36 --> 48
    Enrollment change
    |
    Romvimza (vimseltinib)
    2ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    3ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    3ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    metformin • Romvimza (vimseltinib)
    3ms
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Romvimza (vimseltinib)
    4ms
    Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Romvimza (vimseltinib)
    4ms
    Gamma Oscillation Disruption Induced By Microglial Activation Contributes to Perioperative Neurocognitive Disorders in Aged Mice. (PubMed, J Mol Neurosci)
    Specific depletion of microglia in aged mice, achieved by drinking water supplemented with the colony-stimulating factor 1 receptor (CSF1R)/c-Kit kinase inhibitor PLX3397 for seven consecutive days, resulted in a reduction of postoperative hippocampal neuroinflammation and a significant improvement in cognitive dysfunction. Similarly, perioperative inhibition of microglial activation with minocycline resulted in cognitive improvement...These findings suggest that the activation of hippocampal microglia and the associated neuroinflammatory response following surgery play a crucial role in PND. The underlying mechanism may be related to disturbed gamma oscillations and a reduction in the inhibitory function of PV interneurons.
    Preclinical • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Turalio (pexidartinib) • minocycline
    4ms
    A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Daiichi Sankyo | Trial completion date: Mar 2036 --> Jun 2036 | Trial primary completion date: Jun 2025 --> Jun 2036
    Trial completion date • Trial primary completion date • Adverse events
    |
    Turalio (pexidartinib)
    4ms
    Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New trial • Real-world evidence
    |
    Romvimza (vimseltinib)
    4ms
    Microglial depletion and repopulation differentially modulate sleep and inflammation in a mouse model of traumatic brain injury. (PubMed, Neurobiol Sleep Circadian Rhythms)
    We hypothesized that microglial depletion via PLX5622 (PLX), a colony-stimulating factor 1 receptor (CSFR1R) inhibitor, would exacerbate sleep disturbances and alter inflammatory profiles after TBI, and that microglial repopulation would ameliorate these effects...This study highlights the critical role of microglia in modulating post-TBI sleep and inflammation. Findings suggest differential effects of TBI on sleep depending on microglial depletion or repopulation status, with IL-6 serving as a marker of the inflammatory response in microglia-depleted conditions.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)